Treats major depressive episode associated with bipolar I disorder (bipolar depression). ANDA 208047, held by Dr Reddys. Lurasidone Hydrochloride.
As of Nov 16, 2026, ANDA 208047 (Lurasidone Hydrochloride), held by Dr Reddys, was first approved by FDA on Aug 24, 2021, with 2 approved supplements and 0 published complete response letters.
Lurasidone hydrochloride tablets are indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 24, 2021 | Original application | Approved | None posted |
| Lurasidone Hydrochloride20MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride40MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride60MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride80MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Jun 1, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 1, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 24, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters